Homeobox protein NKX-3.2 (NKX3-2) (NKX3-2)

Homeobox protein NKX-3.2 (NKX3-2), also known as BAPX1, is a critical transcription factor belonging to the NK-2 homeobox family, primarily recognized for its essential role in skeletal development and chondrogenesis (UniProt P78367). It functions as a transcriptional repressor that regulates the patterning of the axial skeleton and the maturation of chondrocytes by controlling the expression of genes such as Runx2 and Sox9 (PubMed: 10433905). Mutations in the NKX3-2 gene are the primary cause of spondylo-megaepiphyseal-metaphyseal dysplasia (SMMD), a rare and severe skeletal disorder (NCBI Gene: 579). In addition to its developmental functions, NKX3-2 has been implicated in oncogenesis, particularly in gastric cancer where it may act as a tumor suppressor, and in chondrosarcoma where its expression levels correlate with tumor progression (PubMed: 22433058). Although NKX3-2 is a significant biological target for understanding skeletal pathologies and certain cancers, it is currently considered a challenging therapeutic target due to the inherent difficulties in drugging transcription factors. There are no FDA-approved drugs that directly target NKX3-2, but it remains a subject of intense research for regenerative medicine and targeted oncology therapies (PubMed: 30126001).

Other names

BAPX1NKX3BBagpipe homeobox protein homolog 1NK3 homeobox 2

Transcriptional repression through sequence-specific DNA binding and recruitment of co-repressors to regulate chondrocyte differentiation and skeletal patterning (PubMed: 10433905).